Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) significantly improved progression-free survival (PFS) versus VRd in newly diagnosed multiple myeloma (NDMM) in transplant eligible (TE; PERSEUS) and transplant-ineligible (TIE; CEPHEUS) populations. Median PFS with DVRd has not been reached in either stud...
P. Sonneveld, S. Zweegman, T. Facon et al.· Journal of Clinical Oncology· 0 citations
In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myelom...
T. Facon, G. Cook, S. Usmani et al.· Leukemia· 0 citations
The phase III CEPHEUS trial (ClinicalTrials.gov identifier: NCT03652064) of patients with transplant-ineligible (TIE) or transplant-deferred newly diagnosed multiple myeloma (NDMM; N = 395) demonstrated improved overall minimal residual disease (MRD) negativity rates among patients achieving ≥complete response and prog...
S. Usmani, T. Facon, V. Hungria et al.· Journal of Clinical Oncology· 0 citations
An NF-κB-associated inflammatory axis underlying poor DR response is underscores an NF-κB-associated inflammatory axis underlying poor DR response and suggests that targeting inflammatory pathways a potential therapeutic avenue warranting further investigation.
Wen-Wen Cheng, S. Gaggero, Lama Hasan Bou Issa et al.· Biomarker Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.